Neurocritical Care

, Volume 4, Issue 1, pp 25–31 | Cite as

A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage

  • Junling Gao
  • Haichen Wang
  • Huaxin Sheng
  • John R. Lynch
  • David S. Warner
  • Lori Durham
  • Michael P. Vitek
  • Daniel T. Laskowitz
Translational Research

Abstract

Introduction

Recent clinical observations demonstrate that the APOE4 genotype increases the development of delayed ischemic deficit and worsens prognosis following aneurysmal subarachnoid hemorrhage (SAH). In the current study, we use targeted replacement mice expressing only human apoE3 or apoE4 to model the isoform-specific effects of apoE following SAH. We then test the hypothesis that an apoE-derived therapeutic peptide reduces vasospasm and improves functional recovery after SAH.

Methods

Experimental SAH was induced in APOE3- and APOE4-targeted replacement mice. For 3 days following injury, daily functional assessments were made. Mice were then sacrificed and the cerebral vasculature visualized to quantify vasospasm. In a separate experiment, C57BI/6 mice were treated with intravenous injection of vehicle, low-dose, or high-dose apoE-mimetic peptide every 12 hours for 3 days post-SAH. Functional endopoints were assessed on a daily basis, followed by measurement of middle cerebral artery diameter.

Results

Mice expressing the apoE4 isoform had greater functional deficit, mortality, cerebral edema, and vasospasm as compared with their apoE3 counterparts. Mice treated with the apoE-mimetic peptide had decreased mortality, functional deficits, and histological evidence of vasospasm as compared with vehicle-treated animals.

Conclusion

Consistent with the clinical literature, the apoE4 isoform is associated with an increased incidence of vasospasm and poor functional recovery after experimental SAH. An apoE-derived peptide represents a novel therapeutic approach for the treatment of SAH.

Key Words

Subarachnoid hemorrhage apolipoprotein E inflammation vasospasm 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Laskowitz DT, Horsburgh K, Roses AD. Apolipoprotein E and the CNS response to injury. J Cerebral Blood Flow Metab 1998; 18:465–471.CrossRefGoogle Scholar
  2. 2.
    Weisgraber KH, Apolipoprotein E. Structure-function relationships. Advances in Protein Chem 1994;45:249–302.Google Scholar
  3. 3.
    Mcarron MO, Muir KW, Weir CJ, et al. The apolipoprotein E epsilon4 allele and outcome in cerebrovascular disease. Stroke 1998;29:1882–1887.PubMedGoogle Scholar
  4. 4.
    Friedman G, Froom P, Sazbon L, et al. Apolipoprotein E-epsilon 4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999;52:244–248.PubMedGoogle Scholar
  5. 5.
    Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997;50:1069–1071.CrossRefGoogle Scholar
  6. 6.
    Lanterna LA, Rigoldi M, Tredici G, et al. APOE influences vasospasm and cognition of noncomatose patients with subarachnoid hemorrhage. Neurology 2005;64:1238–1244.PubMedGoogle Scholar
  7. 7.
    Leung CH, Poon WS, Yu LM, Wong GK, Ng HK. Apolipoprotein E genotype and outcome in aneurysmal subarachnoid hemorrhage. Stroke 2002;33:548–552.PubMedCrossRefGoogle Scholar
  8. 8.
    Tang J, Zhao J, Zhao Y, Wang S, Chen B, Zeng W. Apolipoprotein E epsilon4 and the risk of unfavorable outcome after aneurysmal subarachnoid hemorrhage. Surg Neurol 2003;60(5):391–396.PubMedCrossRefGoogle Scholar
  9. 9.
    Dunn LT, Stewart E, Murray GD, Nicoll JA, Teasdale GM. The influence of apolipoprotein E genotype on outcome after spontaneous subarachnoid hemorrhage: a preliminary study. Neurosurgery 2001;48:1006–1010.PubMedCrossRefGoogle Scholar
  10. 10.
    Niskakangas T, Ohman J, Niemeda M, Ilveskoski E, Kunnas TA, Karhunen PJ. Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage: a preliminary study. Stroke 2001;32:1181–1184.PubMedGoogle Scholar
  11. 11.
    Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol Res 2002; 24:510–516.PubMedCrossRefGoogle Scholar
  12. 12.
    McGirt MJ, Lynch J, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm following subarachnoid hemorrhage. Stroke 2002;33:2950–2956.PubMedCrossRefGoogle Scholar
  13. 13.
    Sullivan PM, Mezdour H, Aratani Y, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997;227:17,972–17,980.Google Scholar
  14. 14.
    Aono M, Bennett ER, Kim KS, et al. Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. Neuroscience 2003;116(2):437–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Laskowitz DT, Goel S, Bennett ER, Matthew WD. Apolipoprotein E suppresses glial cell secretion of TNFα. J Neuroimmunol 1997;76:70–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Laskowitz DT, Thekde S, Han D, Thekde A, Bennet ER. Downregulation of glial activation by apolipoprotein E and ApoE-mimetic peptides. Exp Neurol 2001;167:74–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Lynch JR, Tang W, Wang H, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003;278:48,529–48,533.Google Scholar
  18. 18.
    Lynch JR, Wang, H, Mace B, et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005; 192:109–116.PubMedCrossRefGoogle Scholar
  19. 19.
    McAdoo JD, Warner DS, Goldberg RN, Vitek MP, Pearlstein R, Laskowitz DT. Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett 2005;381:305–308.PubMedCrossRefGoogle Scholar
  20. 20.
    Yokoo N, Sheng H, Mixco J, Homi HM, Pearlstein RD, Warner DS. Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: a comparison with dizocilpine. Anesthesia & Analgesia 2004;99:896–903.CrossRefGoogle Scholar
  21. 21.
    Lynch JR, Pineda JA, Morgan D, et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol 2002;51:113–117.PubMedCrossRefGoogle Scholar
  22. 22.
    Marshall GR, Hodgkin EE, Langs DA, Smith GD, Zabrocki J, Leplawy MT. Factors governing helical preference of peptides containing multiple alpha, alpha-dialkyl amino acids. Proc Natl Acad Sci USA 1990;87:487–491.PubMedCrossRefGoogle Scholar
  23. 23.
    Ratnaparkhi GS, Awasthi SK, Rani P, Balaram P, Varadarajan R. Structural and thermodynamic consequences of introducing alpha-aminoisobutyric acid in the S peptide of ribonuclease S. Protein Eng 2000;13:697–702.PubMedCrossRefGoogle Scholar
  24. 24.
    Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985; 16:562–572.PubMedGoogle Scholar
  25. 25.
    Sheng H, Laskowitz DT, Bennett ER, et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab 1998;18:361–366.PubMedCrossRefGoogle Scholar
  26. 26.
    Horsburgh K, McCulloch J, Nilsen M, Roses AD, Nicoll JA. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. Eur J Neurosci 2000;12:4309–4317.PubMedCrossRefGoogle Scholar
  27. 27.
    Sabo T, Lomnitski L, Nyska A, et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 2000;101:879–884.PubMedCrossRefGoogle Scholar
  28. 28.
    Dietrich HH, Dacey RG. Molecular keys to the problem of vasospasm. Neurosurgery 2000;46:517–530.PubMedCrossRefGoogle Scholar
  29. 29.
    Aono M, Lee Y, Grant ER, et al. Apoliproprotein E protects against NMDA excitotoxicity. Neurobiol Dis 2002;11:214–220.PubMedCrossRefGoogle Scholar
  30. 30.
    Linton M, Gish R, Hubl S, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991;88:270–281.PubMedCrossRefGoogle Scholar
  31. 31.
    Misra U, Gawdi G, Mcmillian M, Pizzo P, Laskowitz DT. Apolipoprotein E and apoE-mimetic peptides initiate a calcium-dependent signaling response in macrophage. J Leuk Biol 2001;70:677–683.Google Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Junling Gao
    • 1
    • 2
    • 6
  • Haichen Wang
    • 1
    • 2
  • Huaxin Sheng
    • 1
    • 4
  • John R. Lynch
    • 1
    • 2
  • David S. Warner
    • 1
    • 3
    • 4
  • Lori Durham
    • 2
  • Michael P. Vitek
    • 2
    • 3
    • 5
  • Daniel T. Laskowitz
    • 1
    • 2
    • 3
    • 4
  1. 1.Multidisciplinary Neuroprotection Laboratories the Department ofDuke University Medical CenterDurham
  2. 2.Department of NeurologyDuke University Medical CenterDurham
  3. 3.NeurobiologyDuke University Medical CenterDurham
  4. 4.AnesthesiologyDuke University Medical CenterDurham
  5. 5.Cognosci Inc.Research Triangle Park
  6. 6.Department of Histology and EmbryologyNorth China Coal Medical CollegeTangshan, HebeiChina

Personalised recommendations